NEW YORK (GenomeWeb News) – Biomodels said today that Swedish Orphan Biovitrum has contracted it to test the possibility of developing a predictive assay to determine which stem cell therapy patients may be at risk for a complication called oral mucositis.
Under the agreement, the Watertown, Mass.-based preclinical drug research firm aims to develop a screening platform to define mucositis risk for patients undergoing conditioning regimens for hematopoietic stem cell transplants (HSCT).